

30 December 2021

Intuitive Investments Group plc
 ("IIG" or the "Company")

Result of Annual General Meeting

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that at the Annual General Meeting held today, all resolutions were duly passed.

The results of the proxy voting are summarised in the table below:

Resolution	Votes For	Votes Against	Withheld
One	24,279,200	0	0
Two	24,279,200	0	0
Three	24,279,200	0	0
Four	24,279,200	0	0
Five	24,279,200	0	0
Six	24,279,200	0	0
Seven	24,279,200	0	0
Eight	24,279,200	0	0
Nine	24,279,200	0	0
Ten	24,279,200	0	0
Eleven	24,279,200	0	0

Change of Investing Policy

The Company's investing policy has now been changed. As a result of these changes IIG will now be able to: invest into a larger number of portfolio companies; be appointed as an investment adviser, or manager to third party funds; and, invest more of its assets into a single investee company. These changes will allow the Board more flexibility in generating shareholder returns.

David Evans, Chairman, commented: *"I would like to thank shareholders for their support by voting in favour of the resolutions proposed at today's Annual General Meeting, in particular for their endorsement of the changes to IIG's investing policy. We look forward to updating shareholders in the New Year with further progress on existing portfolio companies and new investments."*

For further information, please contact:

Intuitive Investments Group plc

David Evans, Executive Chairman
 Robert Naylor, CEO

www.iigplc.com

Via Walbrook PR

SP Angel Corporate Finance LLP - Nominated Adviser

Jeff Keating / David Hignell / Kasia Brzozowska

+44 (0) 20 3470 0470

Turner Pope Investments (TPI) Ltd - Broker

Andrew Thacker / James Pope

+44 (0) 20 3657 0050

Walbrook PR Limited - Media & Investor Relations

Paul McManus/ Sam Allen

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

+44 (0) 7980 541 893 / +44 (0) 7502 558 258



About Intuitive Investments Group plc

The Company is an investment company seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.